Abstract
MYC, one of the most commonly dysregulated proteins in cancer, has long seemed 'undruggable'. Can a clinical-stage cell-penetrating peptide - or precl......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
